Dec 16, 2019 6:00am EST Algernon Pharmaceuticals Appoints Leading Respirologist Dr. Martin Kolb to Its Medical and Scientific Advisory Board
Dec 10, 2019 6:00am EST Algernon Pharmaceuticals to Present at 12th Annual LD Micro Main Event Conference on Wednesday December 11, 2019
Dec 09, 2019 6:00am EST Algernon Pharmaceuticals Selects NP-120 (Ifenprodil) for its Lead Phase 2 Trial for Idiopathic Pulmonary Fibrosis and Chronic Cough
Dec 05, 2019 6:00am EST Algernon Pharmaceuticals’ NP-120 (Ifenprodil) Outperforms Merck’s Phase 3 Drug MK-7264 (Gefapixant) in an Acute Cough Study by 110%
Nov 25, 2019 7:00am EST Algernon Pharmaceuticals Provides Update on its Planned Phase II Clinical Trial
Aug 02, 2019 7:00am EDT Algernon Pharmaceuticals Announces Emoxypine (NP-178), a Top Selling Drug in Russia, as its Lead Drug for Inflammatory Bowel Disease
Jul 31, 2019 7:00am EDT Algernon Pharmaceuticals Announces Russian Athletic Performance Enhancing Drugs Bemethyl (NP-135) and Bromantane (NP-160) Exhibited Potent Anti-Fibrotic Activity in NASH and CKD Studies
Jul 29, 2019 7:00am EDT Algernon Pharmaceuticals Announces Ifenprodil (NP-120) an NDMA Receptor Antagonist as its Lead Drug That Reduced Fibrosis in a Recent Idiopathic Pulmonary Fibrosis Study by 56%
Jul 03, 2019 7:00am EDT Algernon Pharmaceuticals’ NP-120 Reduced Fibrosis in an Idiopathic Pulmonary Fibrosis Study by 56% Outperforming USFDA Approved Treatments Nintedanib and Pirfenidone
